228 related articles for article (PubMed ID: 30838675)
1. Inflammatory linear verrucous epidermal nevus treated successfully with crisaborole ointment in a 5-year-old boy.
Barney E; Prose NS; Ramirez M
Pediatr Dermatol; 2019 May; 36(3):404-405. PubMed ID: 30838675
[TBL] [Abstract][Full Text] [Related]
2. A case of inflammatory linear verrucous epidermal nevus successfully treated with Brodalumab.
Green R; Hunter C; Chia JC
Pediatr Dermatol; 2022 Sep; 39(5):757-760. PubMed ID: 35657009
[TBL] [Abstract][Full Text] [Related]
3. Off-Label Therapeutic Potential of Crisaborole.
Makins C; Sanghera R; Grewal PS
J Cutan Med Surg; 2020; 24(3):292-296. PubMed ID: 32133868
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory linear verrucous epidermal nevus (ILVEN) encompasses a spectrum of inflammatory mosaic disorders.
Atzmony L; Ugwu N; Hamilton C; Paller AS; Zech L; Antaya RJ; Choate KA
Pediatr Dermatol; 2022 Nov; 39(6):903-907. PubMed ID: 35853659
[TBL] [Abstract][Full Text] [Related]
5. Differences in clinical characteristics and lesion proteomics between inflammatory linear verrucous epidermal nevus and local verrucous epidermal nevus.
Yuan T; Lu XH; Tang B; Chang XL; He CF; Wang J; Ci C
J Proteomics; 2022 May; 260():104554. PubMed ID: 35283356
[TBL] [Abstract][Full Text] [Related]
6. An inflammatory verrucous epidermal nevus concomitant with psoriasis: treatment with adalimumab.
Özdemir M; Balevi A; Esen H
Dermatol Online J; 2012 Oct; 18(10):11. PubMed ID: 23122018
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory linear verrucous epidermal nevus associated with erosive monoarthritis.
Bertolin-Colilla M; Alcalá R; Deza G; Polino L; Gallardo F; Pujol RM
Pediatr Dermatol; 2018 Sep; 35(5):e291-e293. PubMed ID: 29974513
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory linear verrucous epidermal nevus in groin and labia with claudication: Successfully treated with photodynamic therapy.
Wei L; Yu L; Zou L; Ma L
Photodiagnosis Photodyn Ther; 2024 Feb; 45():103970. PubMed ID: 38215957
[TBL] [Abstract][Full Text] [Related]
9. The challenge to diagnose a clinical case of inflammatory linear verrucous epidermal nevus: is there any ILVEN associated with human papillomavirus infection?
Godefroy P; dos Reis HL; Ferreira Dde C
Rev Soc Bras Med Trop; 2014; 47(5):668. PubMed ID: 25467274
[No Abstract] [Full Text] [Related]
10. Treatment of psoriasis with crisaborole.
Lee EB; Lebwohl MG; Wu JJ
J Dermatolog Treat; 2019 Mar; 30(2):156-157. PubMed ID: 29812961
[TBL] [Abstract][Full Text] [Related]
11. Carbon dioxide laser: first-line therapy in vulvar inflammatory linear verrucous epidermal nevus.
D'Antuono A; Balestri R; Zauli S; Bardazzi F; Bellavista S; Banzola N; Sgubbi P; Patrizi A
Dermatol Ther; 2012; 25(1):92-4. PubMed ID: 22591503
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory linear verrucous epidermal nevus successfully treated with methyl-aminolevulinate photodynamic therapy.
Parera E; Gallardo F; Toll A; Gil I; Sánchez-Schmidt J; Pujol R
Dermatol Surg; 2010 Feb; 36(2):253-6. PubMed ID: 20402956
[No Abstract] [Full Text] [Related]
13. Extensive, adulthood inflammatory linear verrucous epidermal nevus associated with mucinous nevus.
Vukicevic JS; Milobratovic DJ; Milinkovic MV; Bogdanovic Z
Indian J Dermatol Venereol Leprol; 2011; 77(5):607-8. PubMed ID: 21860165
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory linear verrucous epidermal nevus: A paradigm of progress.
Heymann WR
J Am Acad Dermatol; 2024 Jun; 90(6):1159-1160. PubMed ID: 38552904
[No Abstract] [Full Text] [Related]
16. Adult-onset inflammatory linear verrucous epidermal nevus: Immunohistochemical studies and review of the literature.
Tseng HW; Liao JB; Wei YA
J Cutan Pathol; 2021 Jan; 48(1):140-146. PubMed ID: 32954567
[TBL] [Abstract][Full Text] [Related]
17. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
Stein Gold LF; Spelman L; Spellman MC; Hughes MH; Zane LT
J Drugs Dermatol; 2015 Dec; 14(12):1394-9. PubMed ID: 26659931
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory linear verrucous epidermal nevus responsive to 308-nm excimer laser treatment.
Grgurich E; Gupta N; Owen R; Purcell SM
Cutis; 2018 Aug; 102(2):111-114. PubMed ID: 30235359
[TBL] [Abstract][Full Text] [Related]
19. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
Murrell DF; Gebauer K; Spelman L; Zane LT
J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
[TBL] [Abstract][Full Text] [Related]
20. Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis.
Woo TE; Kuzel P
Skin Therapy Lett; 2019 Mar; 24(2):4-6. PubMed ID: 30970204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
